SOX2 and sarcoma: Taking a lesson from the glioblastoma experimental system cited above, as well as from the largely complementing and overlapping metabolic impact of all the pluripotency transcription factors [70], we can hypothesise that the increased expression of Sox-2 found in our invasive sarcoma cell lines could be the crucial regulatory factor.